Takayasu arteritis (TAK) is a vasculitic disease of unknown cause that preferentially affects the aorta, its major branches, and the pulmonary arteries, resulting in vascular stenoses/occlusions or aneurysms (1) (2) (3) (4) (5) (6) (7) (8) (9) . TAK is most commonly diagnosed between the ages of 18 and 40 years and occurs predominantly in women. Glucocorticoids have been the foundation of treatment in TAK, as they improve systemic symptoms and, in some studies, have been found to improve blood flow through narrowed vessels (1, 10, 11) . However, despite treatment with glucocorticoids, not all patients achieve remission, and sustained remissions are seen in only 28-50% of patients (1, 9) .
Because of these concerns and the substantial morbidity associated with glucocorticoids, other immunosuppressive agents are frequently prescribed in TAK (12) (13) (14) (15) (16) (17) (18) (19) . However, the use of such adjunctive agents with glucocorticoids has been based solely on the observations from retrospective studies or small open-label trials. Since TAK is a rare disease, with an estimated incidence in the US of 2.6 cases per million per year (2) , conducting randomized trials is difficult. Therefore, it has been a high priority and unmet need in TAK to identify a safer, effective therapeutic option beyond glucocorticoids through the conduct of a randomized therapeutic trial in this disease.
The cause of TAK remains unknown, but laboratorybased data support a critical role of activated T cells in disease pathogenesis (20) . Studies of aortic tissue from patients with TAK have demonstrated that the infiltrating cells consist mainly of activated T cells (21) (22) (23) (24) and dendritic cells in the adventitia (25) . Increased expression of T cell costimulatory molecules has also been found in vascular cells and infiltrating cells at sites of inflammation in TAK (23) . Abatacept is composed of the ligand-binding domain of CTLA-4 as well as a modified Fc domain derived from IgG1. CTLA-4 binds to CD80 and CD86 with a higher avidity than that to CD28, thereby acting as a negative regulator of CD28-mediated T cell costimulation. With CTLA-4 as one of its components, abatacept blocks the engagement of CD28 with its ligand and inhibits T cell activation (26) (27) (28) . Abatacept is approved by the US Food and Drug Administration for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis and has a low reported rate of toxicity, with the main side effects being hypersensitivity and infection, most commonly including upper respiratory tract infections, bronchitis, and herpes zoster.
Based on the rationale that blockage of T cell activation might impact disease pathogenesis in TAK, together with the favorable toxicity profile that has been seen with abatacept (29-31), a randomized trial was designed and conducted with the objectives of investigating the efficacy and safety of abatacept in the treatment of TAK.
PATIENTS AND METHODS
Design overview. The protocol for this randomized trial was written by 2 of the authors (CAL and PAM) in collaboration with the Steering Committee of the Vasculitis Clinical Research Consortium and the Rare Diseases Clinical Research Network Data Management and Coordinating Center (DMCC) (additional protocol information can be found at https://www. rarediseasesnetwork.org/cms/VCRC). The original study protocol and all amendments were approved by an independent Data and Safety Monitoring Board and by the Institutional Review Board at each site. There were no significant changes made to the study methods after trial commencement. Research was carried out in compliance with the Declaration of Helsinki, and all patients provided written informed consent.
Setting and participants. The trial was conducted at 11 academic medical centers (additional study site participants within the Vasculitis Clinical Research Consortium are listed in Appendix A). Enrolled patients were individuals with newly diagnosed or relapsing TAK who had active disease within the prior 2 months. All patients met the American College of Rheumatology modified classification criteria for TAK (32) , which included the presence of arteriographic abnormalities compatible with TAK, as determined by conventional dye angiography, magnetic resonance angiography, or computed tomography angiography, as well as at least 1 of the following features: 1) age at disease onset ,50 years, 2) claudication of extremities, 3) decreased brachial artery pulse (in 1 or both arteries), 4) blood pressure difference of .10 mm Hg between the arms, and 5) bruit over the subclavian arteries or aorta. Exclusion criteria included active infection (including chronic infection, infection with the human immunodeficiency virus, hepatitis C virus, hepatitis B virus, or tuberculosis), pregnancy, breastfeeding, cytopenias, recent vaccination with a live agent, history of any malignant neoplasm except basal or squamous cell carcinoma of the skin or solid tumors adequately treated with curative therapy and with absence of disease for at least 5 years, comorbidities that would increase the risk of study participation or that required treatment with glucocorticoids, and prior therapy with a biologic agent given within established time parameters (including infliximab within the past 49 days, adalimumab within the past 28 days, etanercept within the past 21 days, or rituximab either within the past 12 months or for .12 months in cases where there was continued B lymphocyte depletion).
Interventions. All eligible patients were treated with abatacept (Bristol-Myers Squibb) at a dose of 10 mg/kg (500 mg for ,60 kg body weight, 750 mg for 60-100 kg, and 1,000 mg for .100 kg) by intravenous infusion on days 1, 15, and 29 and week 8, together with prednisone at a dosage of 40-60 mg/day that was followed by a standardized tapering schedule (see details in Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40037/ abstract). No other concurrent immunosuppressive agents were permitted during the trial. At week 12, if they were in remission, patients underwent a double-blinded randomization to switch to placebo or to continue to receive abatacept given every 4 weeks thereafter (Figure 1 ). At the time of randomization, all patients were taking prednisone at 20 mg/day, with tapering continuing after randomization such that patients in both treatment arms discontinued treatment with prednisone at week 28. The need to increase the prednisone dosage, or to restart prednisone after discontinuation, for the treatment of TAK was considered a relapse criterion.
In the absence of meeting criteria for early termination, abatacept or placebo was continued until a common closing date, which was 12 months after enrollment of the final patient. Potential reasons for early termination included the following: failure to experience remission by the week 12 visit, disease relapse, pregnancy or breastfeeding, development of malignancy with the exception of basal or squamous cell carcinoma of the skin that has been completely excised, grade 4 toxicity, hypersensitivity reactions to abatacept, noncompliance with study procedures, or discontinuation of treatment when, in the medical judgment of the physician, it was deemed in the best interests of the patient. Patients who experienced a relapse discontinued their study drug and were treated according to best medical judgment. Following discontinuation of their study drug, patients were asked to return for posttreatment visits at weeks 4, 12, and 24, after which time they were considered off study.
Randomization and blinding. Randomization was computer-generated by the DMCC in a 1:1 allocation that was balanced by clinical site, utilizing randomly permuted blocks. Patients and all study investigators were blinded with regard to the randomized treatment assignment.
Assessment and follow-up of outcomes. The assessment used to determine disease activity was obtained in a standardized manner throughout the study. A clinical history, physician examination, and laboratory tests were obtained at each study visit. All patients without contraindications underwent magnetic resonance imaging of the aorta and branches at study entry and at the week 12 randomization. Imaging of the large vessels was then performed regularly at 6-month intervals and at the time of early termination/common close.
The primary end point was duration of remission (relapse-free survival). Remission and relapse were based on the absence and presence of disease activity, respectively. The determination of disease activity was defined according to preestablished clinical and imaging criteria, when these features were not attributable to other causes. Clinical criteria included the following: a sustained fever of .388C for more than 1 week, vascular pain/tenderness producing symptoms such as carotidynia, scalp tenderness, or temporal artery abnormalities that were present for .1 day and nonfleeting, headache that was present for .1 day, nonfleeting, not fully relieved with nonopioid analgesics, and not typical for any preexisting form of headaches that may have been experienced by the patient, ischemic retinopathy, optic neuropathy, visual loss, tongue/jaw pain and/or claudication, transient cerebral ischemia, stroke, extremity claudication, or symptoms/ signs attributed to TAK by the investigator that necessitated reinstitution or increase in glucocorticoids. Musculoskeletal symptoms or fatigue/malaise could be considered to be features of active disease if they occurred in combination with an erythrocyte sedimentation rate (ESR) of .40 mm in the first hour by the Westergren method or a C-reactive protein (CRP) measurement above the laboratory normal limit. An elevation in acute-phase reactant levels was not considered indicative of disease activity in the absence of clinically compatible disease manifestations. Imaging features of active disease were the development of new vascular stenosis or aneurysm in new vascular territories, as seen by magnetic resonance, computed tomography, or conventional dye arteriography. Determination of relapse was assessed by both the site investigator and study principal investigator during the blinded phase and reaffirmed by the study team following the end of the trial. No changes were made to the outcome definitions during the course of the trial.
The secondary end point was toxicity. All adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (details available at http://ctep.cancer.gov). Study visits and data collection occurred at screening, at baseline, at each infusion of study drug, at early termination/common close, and at the posttreatment visits.
Statistical analysis and sample size determination. The 12-month relapse-free survival rate in patients with TAK treated with prednisone was estimated to be 30% based on previously reported values in the literature (9) . The planned sample size for the trial of 30 randomized patients was based on an 80% probability of detecting a clinically meaningful difference between treatment arms, set as a 30% improvement in the relapse-free survival rate and utilizing a one-sided alpha value of 0.1.
Kaplan-Meier curves of relapse-free survival were constructed, and differences in treatment arms were compared using the log rank test. The analysis of the primary outcome was based on intent-to-treat. The secondary study end point was toxicity. Adverse events were recorded throughout the trial and analyzed after randomization with tabulation by treatment arm. The frequency of occurrence of each event was compared for treatment differences by Fisher's exact test.
Safety monitoring and guidelines for stopping treatment. Conduct of the study was overseen by an independent Data and Safety Monitoring Board and the Institutional Review Board at each study site. Rules for halting new patient accrual were established prior to trial initiation and consisted of any deaths that were possibly, probably, or definitely related to the study drug or any grade 4 toxicities that were probably or definitely related to the study drug.
RESULTS
Patient population. There were 39 patients with TAK who provided their written informed consent and underwent protocol screening between February 2009 and January 2014 (at the determined end date of the study) 
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LANGFORD ET AL ( Figure 2 ). Five of the 39 patients were not eligible, as they chose to not proceed further within the study; 34 patients received the study drug. Eight of these 34 patients withdrew from the study, had a disease relapse, or did not achieve remission by week 12, resulting in a randomized study population of 26 patients. The baseline clinical and demographic features of the 26 randomized patients are listed in Table 1 . There was no difference in baseline characteristics between the study arms. Twenty-two of the 26 randomized patients were enrolled at the time of a relapse. The 4 newly diagnosed patients were randomized to the placebo arm. There was no statistically significant difference in the prior use of nonglucocorticoid immunosuppressive medications between patients in the 2 treatment groups (Table 1) . Of the 26 patients, 11 were randomized to receive abatacept and 15 to receive placebo. Twenty-five patients met the end point of relapse or sustained remission at week 64. One patient randomized to receive abatacept was withdrawn by the investigator prior to week 64, for a comorbidity that required the long-term use of prednisone. This patient was included in the intent-to-treat analysis and was in remission at the last available follow-up.
Efficacy assessments. In the intent-to-treat analysis of the 26 randomized patients, the relapse-free survival rate at 12 months was 22% for those receiving abatacept and 40% for those receiving placebo (P 5 0.853) ( Figure  3 ). There was no difference in the median duration of remission among those who received abatacept (5.5 months) compared to those who received placebo (5.7 months; P 5 0.125).
The relapses observed during the trial reflected typical characteristics of TAK and consisted of vascular and constitutional features (Table 2) . Three patients, all of whom were randomized to receive placebo, met radiographic end points with development of a new vascular lesion in a previously unaffected territory. Elevations of the Figure 2 . Randomization assignment at week 12. All patients were initially treated with abatacept and prednisone. At week 12, those in remission underwent a blinded randomization at a 1:1 ratio to receive placebo or to continue to receive abatacept. All randomized patients were included in the intent-to-treat analysis. ESR and/or CRP levels above the normal range were seen in all patients who experienced a relapse. Of the 8 patients who remained in remission (3 in the abatacept group and 5 in the placebo group), 2 declined to return for posttreatment visits (see Supplementary Table  2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40037/abstract). One patient who had received abatacept had a relapse 12 weeks after the common close date. The remaining 5 patients all remained in remission during the extended follow-up period through posttreatment week 24.
A prespecified subset analysis was performed on the population of patients who relapsed or were in remission at week 64. Among this group of 25 patients, no difference between the study treatment arms was seen (P 5 0.873).
Adverse events. Overall, 114 adverse events occurred in 28 patients who received the study drug, including 24 serious adverse events in 15 patients. There was no difference in the frequency or severity of adverse events between the treatment arms, including the rate of infection or the rate of serious adverse events ( Table 3) . Five of the serious adverse events occurred before week 12. One patient randomized to receive abatacept was hospitalized 6 times for chest pain, which was determined on each occasion to be noncardiac and nonvascular in origin. No deaths occurred during the study.
A total of 51 infections in 19 patients was reported during the trial, with 7 of the infections requiring hospitalization (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40037/abstract). Eleven infections in 8 patients occurred within the first 12 weeks, of which 2 were serious adverse events. Except for 2 infections that occurred in patients who did not undergo randomization, the remaining 49 infections developed in the randomized study population. Of these 49 infections, 13 occurred in patients in the abatacept study arm, with the remaining 36 developing in those who were randomized to receive placebo. There was no statistically significant difference in the frequency of infections between the treatment arms. The total number of infections was strongly influenced by the presence of multiple infections in some patients. Three patients in the placebo arm had $5 infections, which largely consisted of recurrent infections of the upper airways and urinary tract. Of the 34 treated patients, 1 developed a malignancy during the study period, which was a breast carcinoma diagnosed shortly after the day 29 abatacept infusion.
DISCUSSION
In this trial, patients with TAK who achieved remission and were randomized to continue abatacept had a statistically similar rate of relapse-free survival compared to those who were randomized to receive placebo. Because a standardized prednisone taper was applied to patients in both treatment arms, there was, by definition, no difference in the total prednisone dosage or duration between the study arms. Although the study results unfortunately did not provide supportive evidence of the efficacy of abatacept in this TAK study population, this is the first randomized controlled trial ever conducted in patients with TAK and provides many important insights with regard to the conduct of clinical trials in this disease and raises intriguing questions and future directions for research into this disease.
Safety was an important secondary end point of this study. Utilizing a study design in which all patients initially received abatacept in conjunction with high-dose prednisone provided the opportunity both to gain initial efficacy data and to assess the safety of abatacept, particularly with regard to whether there was any increased risk of infection or other side effects. In comparing the 2 study arms, there was no difference in the type or severity of adverse events seen between those randomized to receive abatacept and those randomized to receive placebo. Moreover, there was no suggestion of a high frequency of infection during the first 12 weeks. Interestingly, a higher overall number of infections occurred in patients randomized to receive placebo as compared to those receiving abatacept. In reviewing the pattern of these infections, we found that this frequency was heavily influenced by a small number of patients who had recurrent upper airway and urinary infections. These infections can occur commonly in young patients and are likely reflective of the population affected by TAK.
This trial has several important strengths. The study was conducted by clinician investigators who are experienced in the care of patients with TAK and in the evaluation of such patients in research studies. Assessing disease activity in TAK is challenging and there are no wellstandardized validated outcome measures for such assessments (33, 34) . The definitions of disease activity used in this trial were determined collectively by the steering committee of the VCRC. These definitions were prespecified within the protocol and required a higher burden of evidence for those features that were the most subjective. The definitions that were used were based on both clinical and imaging parameters, and they reflect the definitions that are applied by practicing physicians in the routine care of patients. Moreover, all relapses were adjudicated by multiple investigators during the blinded phase. Review of the disease characteristics of all relapses (Table 2) indicates that these events were exactly the type seen in practice and include clinical manifestations fully consistent with flares of disease.
The inclusion of imaging findings as a parameter of active disease and the protocol-defined schedule of advanced imaging of the large arteries were other major strengths of the study, and were a critical feature of assessment of a disease known to have asymptomatic progression of serious vascular disease. In addition, the use of a timeto-event analysis both provided greater power for this small sample size and is highly clinically relevant for this disease, which sometimes has long periods between flares. There are several limitations to consider in assessing these results. The relatively small sample size raises the possibility that this study failed to detect a difference between treatment arms that actually exists (Type II error). This study sought to detect a large difference between study arms that would be clinically meaningful, and therefore a smaller difference may not have been detected. However, the results indicate that a much larger sample size would be needed to detect smaller treatment differences, and the clinical utility of using a biologic agent to achieve a small benefit would be difficult to justify. Furthermore, 22 of the 26 randomized patients had relapsing TAK, which raises the question as to whether the results were influenced by enrolling a population with a predilection for disease recurrence. However, the characteristics of this study population are reflective of the disease course of TAK, in which treatment for relapse would be a common and important clinical application for any new therapeutic agent. The high frequency of relapsing patients seen in the enrolled population also demonstrates that although focusing on newly diagnosed patients in clinical trials is often considered desirable, this may not be feasible in TAK trials, given the rarity of the disease and its relapsing nature.
This was the first-ever randomized trial to be performed in patients with TAK. In conducting this study, a great deal was learned about the challenges of performing a sufficiently powered trial in this disease. TAK is one of the least common forms of primary systemic vasculitis. Even with the dedicated participation of centers that have an established referral base for patients with vasculitis, enrollment required perseverance and careful planning. Patients with TAK are eager investigational partners who want to identify treatment options beyond glucocorticoids, as evidenced in our trial, in which only 1 patient withdrew before randomization and no other withdrawals occurred prior to the follow-up time point at 64 weeks. Nonetheless, family and work responsibilities faced by the young population in whom this disease occurs can make it more difficult for them to participate in clinical trials, particularly studies that involve frequent visits over the extended time course necessary to reach study end points in this form of vasculitis.
The results from this trial also pose interesting questions with regard to where TAK may fit within the spectrum of large vessel vasculitis. In giant cell arteritis (GCA), a randomized trial examining the efficacy and safety of abatacept that was conducted by this same investigator group using an identical design, found that treatment with abatacept combined with glucocorticoids resulted in a longer duration of relapse-free survival than did treatment with prednisone alone (35) . GCA and TAK share many common features in that both are large-vessel, granulomatous vasculitides that can have similar arterial distributions (36,37), and laboratory-based studies have supported both as being antigen-driven diseases (38, 39) . Whether GCA and TAK are unique entities or whether they represent part of a single clinical spectrum is an ongoing question (36) . The divergence in therapeutic efficacy seen in these parallel trials provides strong evidence of the need to continue scientific investigations to better understand the underlying immunologic nature of these diseases, which in turn may guide therapeutic strategies.
In conclusion, this study found that in patients with TAK, treatment with abatacept combined with glucocorticoids did not provide a longer duration of relapse-free survival when compared to treatment with prednisone alone. This trial demonstrated the ability to conduct rigorous randomized trials in TAK and provided knowledge of, and insight into, strategies to aid the conduct of future comparative trials in this disease.
